Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

nts who discontinued study therapy in ETV-027, and subsequently restarted treatment in rollover study ETV-901, with a greater than 60 day gap between end of treatment in study ETV-027 and start of treatment in study ETV-901.

    -- ETV-027 compared 0.5 mg of BARACLUDE vs. 100 mg of lamivudine in
nucleoside-naive chronic HBeAg-negative chronic hepatitis B patients.
-- Rollover study ETV-901 was established as an open-label, follow-up
protocol for patients in phase II and III studies of BARACLUDE.
-- Due to ongoing blinding of study ETV-027, most patients retreated in
ETV-901 initially received a combination of 1 mg of BARACLUDE plus 100
mg of lamivudine, and were subsequently switched to 1 mg of BARACLUDE

The analysis cohort was defined regardless of treatment response at the end of dosing in study ETV-027, and independent of virologic or ALT measurements at the start of dosing in study ETV-901. During off-treatment follow-up, the majority of patients had recurrent levels of hepatitis B virus in the blood (viremia) and increases in ALT.

    Data Results
At the end of dosing for study ETV-027:
-- 94 percent (n=93/99) of the re-treatment cohort had undetectable viral
-- 78 percent (n=77/99) had ALT normalization
At entry into ETV-901:
-- Four percent (n=4/99) of patients had undetectable viral load
-- Eight percent (n=8/97) of patients had ALT normalization
Following re-treatment in study ETV-901:
-- 93 percent (n=82/88) of patients had undetectable viral load (HBV DNA
<300 copies/mL) by week 48 of re-treatment with BARACLUDE
-- 83 percent (n=79/95) of patients had ALT normalization (ALT less than
or equal to 1 times the upper limit of normal) by week 48 of re-
treatment BARACLUDE
Adverse events in study ETV-027/901 re-treatment cohort:
-- 67 percent (n=66/99) of patients experienced an adverse event. The most
common adverse events occurring in greater than ten percent of patients
were abdominal pain, fa

Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
(Date:5/21/2015)...  Cardica, Inc. (Nasdaq: CRDC ) today announced that ... the company,s vice president of operations, was granted an option ... a per share exercise price of $0.43, the closing trading ... pursuant to Cardica, Inc.,s Inducement Plan, which was approved by ... 5653(c)(4) of the Nasdaq Global Market for equity grants to ...
(Date:5/21/2015)...  Heidrick & Struggles (Nasdaq: HSII ), the ... consulting and culture shaping worldwide, strengthens ... announcing the addition of Tim Dietlin to ... Dietlin has extensive life sciences and professional ... Medical and Commercial functions to increase productivity, drive transformational ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... FORT WORTH, Texas, March 31, 2011 Recent information ... from March 2 -4, 2011 indicates a rise in ... Hip Replacement System which was manufactured and marketed by ...  The British Orthopaedic Association has released a summary of ...
... MORRISTOWN, N.J., March 31, 2011 Watson Pharmaceuticals, ... that it is initiating launch activities of Nulecit™ ... FDA approval of GeneraMedix Inc.,s, Abbreviated New Drug ... therapeutically equivalent alternative to Sanofi-Aventis, Ferrlecit ® . ...
Cached Medicine Technology:Failure Rate of DePuy ASR XL Hip Implant Rising 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
(Date:5/22/2015)... 2015 DMG Productions announces the upcoming ... broadcast on Friday, May 29, 2015 at 7:30 a.m. ... In this episode Innovations will explore Interstate Restoration, a ... quickly through disaster recovery and restoration. , Additionally, the ... collaboratively to develop and deliver training and education in ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened ... years they have concentrated their focus to working with ... Because of this growth and their goals to better ... Denver, Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, ... dental offices, dental start ups, orthodontic practices, pediatric dental ...
(Date:5/22/2015)... 2015 Puritan Medical Products, a ... medical, diagnostic, environmental, and forensics industries celebrates 96 ... in the US. At a time when countless ... US, Puritan remains committed to designing and manufacturing ... Maine facility. , Since 1919, Puritan has focused ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Pro3rd ... thirds designed exclusively for Final Cut Pro X. Pro3rd ... any design. , Intuitive on-screen-controls allow users to ... third. Reflections, colors, layouts, and much more can be ... , Pro3rd Impression comes packed with ...
Breaking Medicine News(10 mins):Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... Jose "El Nino" Temprana, a 105-year-old exile who was detained for ... when he became a US citizen at a ceremony in Miami. ... find himself a wife. ,And the former fisherman is ... once plotted to assassinate. ,"He's far less healthy than ...
... about it for fourteen years and when he finally started it ... Ark. ,Huibers, a jovial man with a smile ... after having a dream that the Netherlands was flooded. ... I like to talk about God and tell the story," Huibers ...
... your pet could prove bad for your lungs. ... from the cats skin could irritate the lungs and exacerbate ... specific allergy to the animals. Of course the problem is ... kind or another. ,A Europe-wide study by a ...
... visits to hospitals and doctors, new data suggests . ... of increased birth rates, such as those during the economic ... have put the generation's birth years at 1946 to 1964. ... booming, prosperous America, admired and envied by other countries. ...
... issue of The American Journal of Medicine, researchers from ... that people 45 to 64 years of age who ... for cardiovascular disease (CVD) and reduce their death rate. ... eating at least 5 fruits and vegetables daily, exercising ...
... Jammu and Kashmir has allegedly committed suicide in her home ... Razdan of the Engineering Regiment was found hanging by her ... quarters at Kunjwani on the outskirts of this winter capital ... a nearby market area and found the door locked from ...
Cached Medicine News:Health News:The American Dream Comes True for 105-year-old Cuban 2Health News:Dutchman Rebuilds Noah's Ark to Spread His Faith 2Health News:Dutchman Rebuilds Noah's Ark to Spread His Faith 3Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 3Health News:As the US Population Ages, Hospital and Doctors Visits Shoot Up 2Health News:Healthy Lifestyle can Reduce Cardiovascular Risk 2
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
The Duet EnCompass Pelvic Floor Diagnostic System is the only equipment specifically designed to perform urodynamics, anorectal manometry, EMG and pudendal nerve latency studies on a single software ...
... The Corkscrew FT II (fully threaded) is ... designed to be inserted flush with the ... and anchor stability. The full thread design ... anchors with protruding eyelets. Especially advantageous when ...
... Corkscrew Parachute Tissue Anchor allows one step fixation ... ideal for arthroscopic knotless rotator cuff repair in ... has an outside thread diameter of 5 mm ... #2 FiberWire suspension sutures securely hold a thin, ...
Medicine Products: